// App-Quantinova.ai

1467 : Role of MRD in Ph+ Pediatric Acute Lymphoblastic Leukemia Patients Treated with and without Tirosine Kinase Inhibitor in the Esphall Study

Researchers

Presenter

  • Giovanni Cazzaniga

Principal Investigators

  • Martin Schrappe

  • Rob Pieters

  • Jan Stary

  • Gabriele Escherich

  • Jeremy Hancock

  • Maurizio Aric-

  • Silja Rottgers

  • Germany

  • Vaskar Saha

  • Andrea Biondi

  • Maria Grazia Valsecchi

  • Paola de Lorenzo

  • Anders Castor

  • Sweden

  • Giovanna Lucchini

  • Virginie Gandemer

Medical Centers

  • CEEGOG, Prague, Czech Republic

  • Switzerland, Kiel, Germany

  • Denmark, Norway, Finland, Iceland, Lund, Sweden

  • Modena, Italy

  • Switzerland, Kiel, Germany

  • Bristol Genetics Laboratory, Childrens Cancer and Leukaemia Group UK, Bristol, United Kingdom,

  • Department of Clinical and Preventive Medicine, University of Milano-Bicocca, EsPhALL Trial Data Center, Monza, Italy

  • Rennes, France

  • Hamburg, Germany

  • CCC-NL, Rotterdam, Netherlands

  • Firenze, Italy

  • Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer, University of Manchester, Childrens Cancer and Leukaemia Group CCLG, Manchester, United Kingdom

Locations

  • Czech Republic

  • Italy

  • Netherlands

  • Germany

  • United Kingdom

  • France

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Ph chromosome

  • Telomerase reverse transcriptase

  • T-cell receptor

Drug/Treatment

  • Imatinib

  • IkT001

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved